Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxylamine succinate + pyridoxine hydrochloride
- Development stage
- Unknown
- Lead developer
- RG Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Envepe is a fixed-dose combination tablet containing doxylamine succinate (an antihistamine) and pyridoxine hydrochloride (vitamin B6). It is marketed by RG Pharmaceutica in Pakistan and is specifically indicated for the treatment of nausea and vomiting of pregnancy (morning sickness) in patients who do not respond to conservative management. Doxylamine acts as an antagonist at histamine H1 receptors and muscarinic acetylcholine receptors, which helps suppress nausea and vomiting signals in the brain. Pyridoxine serves as an essential cofactor in various metabolic processes and neurotransmitter synthesis, which is thought to synergistically alleviate morning sickness symptoms.
- Brand names
- BendectinBonjestaDiclectinDiclegisEnvepe
- Other names
- doxylamine + pyridoxinedoxylamine succinate and pyridoxine hydrochloride
02
Targets
HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)CHRM4 (M4)CHRM3 (M3)CHRM5 (M5)CHRM2 (M2)
Beyond the preview
Go deeper on doxylamine succinate + pyridoxine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxylamine succinate + pyridoxine hydrochloride.